ScreenerHero

CALC CalciMedica, Inc.

NAS · US · Healthcare · Biotechnology · calcimedica.com
1.480USD-0.67%Mkt Cap: 10.11M $P/E: —

CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora,…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap10.11M USD
Enterprise Value757.15K USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-29.56M USD
Revenue/Share—
Last Price1.480 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees15
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.91
PEG—
EV/EBITDA-0.04
EV/Revenue—
P/S—
P/B1.66
EPS (TTM)-6.63
EPS (Forward)-1.63
52W Range
1.4200% of range36.00
52W High36.00 USD
52W Low1.420 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE445.14%
ROA-217.51%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-21.18M USD
CapEx (TTM)28.00K USD
FCF Margin—
FCF Yield-104.26%
Net Debt-9.42M USD
Net Debt/EBITDA0.48
Balance Sheet
Debt/Equity-1.46
Current Ratio5.58
Quick Ratio5.33
Book Value/Sh0.90 USD
Cash/Share2.73 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:5
Split DateAug 31, 2026
Analyst Consensus
Rating—
Target (Mean)50.00 USD
Upside (mean)+3278.4%
Target Range30.00 USD – 75.00 USD
30.00+3278.4% to mean75.00
# Analysts3
Ownership
Shares Out.6.83M
Float3.79M
Insiders18.53%
Institutions57.51%
Short Interest
Short Ratio1.1d
Short % Float2.95%
Short % Out.1.64%
Shares Short111.70K
Short (prev mo.)64.65K
Technical
SMA 502.622 (-43.5%)
SMA 2006.683 (-77.9%)
Beta1.10
S&P 52W Chg16.45%
Avg Vol (30d)69.01K
Avg Vol (10d)43.98K
Technical Indicators
RSI (14)27.4
MACD-0.3319
MACD Signal-0.3600
MACD Hist.+0.0282
BB Upper2.245 USD
BB Middle1.800 USD
BB Lower1.355 USD
BB Width49.47%
ATR (14)0.1753 USD
Vol Ratio (20d)0.10x